Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis
Alimentary Pharmacology & Therapeutics2024Vol. 61(3), pp. 444–455
Citations Over TimeTop 10% of 2024 papers
Alfredo J. Lucendo, Óscar Nantes, Alex Straumann, Luc Biedermann, Albert J. Bredenoord, Danila Guagnozzi, Leonardo Blas‐Jhon, Anna Wiechowska‐Kozłowska, Simon Weidlich, Ulrike von Arnim, C. Santander-Vaquero, Antonia Perelló, Isabel Pérez‐Martínez, Jésus Barrio, Michael Vieth, Ghazaleh Gouya-Lechner, Evan S. Dellon
Abstract
ESO-101 was superior to placebo in reducing oesophageal eosinophilia. The device was safe and well tolerated in adults with EoE, supporting the continued development of ESO-101 for the treatment of EoE (Trials.gov No.: NCT04849390; Eu-CT No.: 2020-000082-16).
Related Papers
- → ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE)(2013)1,149 cited
- → Do endoscopic features suggesting eosinophilic esophagitis represent histological eosinophilia?(2013)27 cited
- → A206 DUPILUMAB TREATMENT REDUCES THE FREQUENCY OF DYSPHAGIA DAYS AND ACTIONS TO RELIEVE DYSPHAGIA IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE): RESULTS FROM THE PHASE 3 LIBERTY EOE TREET STUDY(2024)1 cited
- → Esophageal polyp in a teenage boy with eosinophilic esophagitis(2022)1 cited
- → THE SAFETY AND TOLERABILITY CHARACTERISTICS OF MOMETASONE FUROATE/FORMOTEROL COMBINATION THERAPY IN PATIENTS WITH PERSISTENT ASTHMA: FINDINGS FROM THE PHASE III CLINICAL DEVELOPMENT PROGRAM(2009)